BAM
INO icon

Byrne Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Byrne Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Hold
4
– – ﹤0.01% 588
2026
Q1 		$7 Hold
4
– – ﹤0.01% 562
2025
Q4 		$7 Buy
+4
New +$9 ﹤0.01% 556

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Byrne Asset Management's INO Position: Q2 2026 in Review

Byrne Asset Management held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 4 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #588.

Byrne Asset Management first reported a position in INO in Q4 2025 and has held it in 3 quarters since. The position peaked at $7 in Q1 2026. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Byrne Asset Management held 4 shares of Inovio Pharmaceuticals worth $4 as of Q2 2026.
  • Byrne Asset Management left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Byrne Asset Management's portfolio in Q2 2026, its #588 holding.
  • Byrne Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Byrne Asset Management's Inovio Pharmaceuticals position peaked at $7 in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.